difficult to assess. A primary malignancy is extremely unusual in giant cell tumors however malignant transformation in secondary tumors (tumors that recur several years later in the same location as an initial benign giant cell tumor, following surgical or radiotherapy) is more common (6). The prognoses of malignant giant cell tumors are poor and are that of high grade sarcomas (4) Examination of an open biopsy specimen showed a high-grade malignant fibrous histiocytoma with some areas rich in giant cells. After five courses of caffeine assisted intraarterial chemotherapy, the tumor was resected with an adequate margin, and the defect was reconstructed with an implanted prosthesis of corresponding shape Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report. Park A(1), Cipriano CA(1), Hill K(1), Kyriakos M(1), McDonald DJ(1). Author information: (1)Departments of Orthopaedic Surgery (A.P., C.A.C., and D.J.M.) and Pathology (K.H. and M.K.), Washington University School of Medicine, St. Louis, Missouri
Background: Primary and recurrent giant cell tumor of bone is typically benign; however, rarely giant cell tumor of bone can undergo malignant transformation. Malignancy in giant cell tumor of bone may be primary (adjacent to benign giant cell tumor of bone at first diagnosis) or secondary (at the site of previously treated giant cell tumor of bone). Malignant giant cell tumor of bone has a poor prognosis; it is important to distinguish malignant from benign lesions to facilitate appropriate. The malignant transformation of giant cell tumor (GCT) of bone is a relatively rare phenomenon. The diagnosis in most cases is unexpected and is usually discovered incidentally upon pathological analysis of the resected specimen. Malignant GCTs are divided into primary and secondary forms The malignant transformation of conventional giant cell tumor of bone (GCTOB) is rare and usually occurs with irradiation. Here we report two neglected cases of conventional GCTOB with spontaneous malignant transformation at 11 and 16 years after initial diagnosis Giant cell tumor of bone (GCTB) is a benign tumor with a tendency for local recurrence. Secondary malignant GCTB is rare, occurring in less than 2 % of GCTB cases. Mechanisms of malignant transformation of GCTB remain unclear. We examined 43 cases of GCTB (38 conventional cases, two lung implantatio Malignant giant cell tumor of bone: GCTB can undergo malignant transformation; malignancy in GCTB can be primary (nodule of highly pleomorphic mononuclear cells present within an otherwise conventional GCTB at first diagnosis) and secondary (after treatment of GCTB) (Technol Cancer Res Treat 2019;18:1533033819840000, Virchows Arch 2012;460:327
. Therefore, when benign giant cell tumor suspicious malignant transformation, it is necessary. Giant cell tumor of bone is an uncommon benign tumor that frequently recurs locally. Spontaneous malignant transformation of conventional giant cell tumor of bone is rare and usually occurs with irradiation.This article describes a case of malignant transformation of a giant cell tumor 41 years after initial curettage and subsequent resection. A 68-year-old man presented with a 6-month history of left hip pain
Late malignant transformation of a benign giant-cell tumor of bone. A case report. Sakkers RJ(1), van der Heul RO, Kroon HM, Taminiau AH, Hogendoorn PC. Author information: (1)Department of Orthopaedic Surgery, Leiden University, The Netherlands. PMID: 9052550 [Indexed for MEDLINE] Publication Types: Case Reports; MeSH term It accounts for approximately 20% and 5% of benign and primary bone tumors, respectively. Very rarely, GCTB undergoes a sarcomatous transformation into a malignant type , , . According to the definition, malignant giant cell tumor of bone (MGCTB) can be divided into the primary and secondary types . Primary MGCTB is a type of tumor in which. The malignant transformation of giant cell tumor (GCT) of bone is a relatively rare event. Most cases are 'secondary' tumors, usually arising in lesions that have been treated previously with radiotherapy. Less commonly, secondary malignancy occurs in GCTs that have been treated surgically
Two cases of malignant lesions are reported, both of which arose secondary to an originally benign giant cell tumor (GCT) of bone. The first case was a typical benign GCT, which occurred in the left proximal tibia of a 31-year-old woman. The tumor was treated by curettage and bone grafting. However, it recurred twice during 15 years of follow-up. The second recurrence showed that the lesion. Takesako H, Osaka E, Yoshida Y, Sugitani M, Tokuhashi Y: Secondary malignant giant cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as fever of unknown origin: a case report. J Med Case Rep. 2016, 10:47. 10.1186/s13256-016-0833-
So-called malignant giant cell tumor is a controversial issue. 4 Uncommon bone tumors develop that have the clinical, topographic, and general microscopic features of giant cell tumor but also show clear-cut evidence of malignancy in the mononuclear stromal component It is not uncommon for sarcomatous transformation of giant cell tumor (GCT) of bone to occur after radiation, but rarely does malignant transformation occur spontaneously, with less than 15 cases reported up to 1995. Only four of these cases have been documented in detail Our purpose was, through the comparison of the characteristics of time-intensity curve on triple-phase dynamic contrast-enhanced MRI among groups of giant cell tumor of bone (GCTB), recurrent benign giant cell tumor of bone (RBGCTB), and secondary malignant giant cell tumor of bone (SMGCTB), to find clues to predict the malignant transformation of GCTB T Marui, T Yamamoto, H Yoshihara, etal : De novo malignant transformation of giant cell tumor of bone Skeletal Radiol 30: 104 - 108, 2001 Crossref, Medline, Google Scholar: 13. MG Rock, FH Sim, KK Unni, etal : Secondary malignant giant-cell tumor of bone GCTB is associated with a higher risk of malignant transformation. Abstract: In giant cell tumor of bone (GCTB), an intermediate malignant bone tumor, approximately 4% of all cases undergo malignant transformation. Accordingly, we analyzed risk factors for malig-nant transformation of GCTB treated without radiotherapy
Malignant transformation of benign giant cell tumor of bone can be occurred within 5 years. Therefore, when benign giant cell tumor suspicious malignant transformation, it is necessary to do more aggressive treatment At our institution, 14 patients with giant cell tumor of bone have had recurrences (from a total of 40 patients with GCT with 4 patients lost to follow-up <6 months after treatment); of these, two patients have had malignant transformation: the two patients reported herein who also represent half of the patients treated with denosumab for at least six months (average follow-up: 83 months, range of 6-154) Background: Malignant transformation of giant cell tumors of bones, that is, secondary malignant giant cell tumor of bone, is rare. The most common symptoms are local pain and swelling. There are no prior reports of giant cell tumor of bone with fever of unknown origin at the onset. Here we present a case of a secondary malignant giant The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3 family of histone genes H3‐3A or H3‐3B; however, the same mutation is occasionally found in primary malignant bone tumours which share many features with the benign variant.Moreover, lung metastases can occur despite the absence of malignant histological features in either the primary or.
[Malignant transformation of a giant cell tumor of the bones]. [Malignant transformation of a giant cell tumor of the bones]. CONTZEN H. Bruns' Beitrage zur Klinischen Chirurgie, 01 Jun 1955, 190(4): 385-393 Language: ger PMID: 13250260 . Share this article. Late malignant transformation of a benign giant-cell tumor of bone. A case report. The Journal of Bone and Joint Surgery. P. Hogendoorn. Download with Google Download with Facebook. or. Create a free account to download. Late malignant transformation of a benign giant-cell tumor of bone. A case repor Spontaneous malignant transformation of giant cell tumor (GCT) of the bone is not uncommon [6, 7, 9-11, 29].Malignant transformation has been defined by many authors as a sarcoma associated with a benign typical GCT at presentation or as a sarcoma arising at the site of a preexisting GCT [6, 11] resulting in osteosarcoma, fibrosarcoma, or malignant histiocytoma [5, 31] Transformation is usually recognized several years after radiation therapy and the tumor often then has the microscopic appearance of a The pre- sented case fulfills the criteria of Dahlin et al.' con- cerning malignant giant-cell tumors. They state that a malignant tumor must have histologic evidence of th Malignant giant cell tumor Postoperative radiation therapy is used with some success in achieving local control. 440 Malignant transformation is extremely rare. It may occur after treatment, especially after radiation therapy, or de novo. Usually the patients are approximately one decade older than patients with GCT
Case: A 64-year-old man with a history of giant cell tumor of bone (GCTB) in the fibula 7 years earlier developed a recurrence with histologic features of osteosarcoma. Both the primary GCTB and the secondary osteosarcoma were found to have the H3F3A gene mutation. Despite immediate above-the-knee amputation, the patient died of respiratory failure because of lung metastases 3 months later The current authors report a patient in whom a malignant fibrous histiocytoma developed long after a benign giant cell tumor of bone was removed from the same site. Twenty-five years after a benign giant cell tumor of the lateral condyle of the proximal tibia had been treated by curettage and iliac bone grafting without radiotherapy, a 53-year.
Park A, Cipriano CA, Hill K, et al. Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report. JBJS Case Connect 2016; 6:e78. Cheng YY, Huang L, Kumta SM, et al. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration We present the case of a patient with malignant transformation of a liposclerosing myxofibrous tumor. The patient had a histologically confirmed liposclerosing myxofibrous tumor that, during a course of 22 months, spontaneously transformed into a lesion appearing like a benign giant cell reactive lesion and subsequently into a high-grade bone sarcoma
PDF | On Jul 21, 2013, Joseph R Grajo and others published Secondary Malignant Transformation of Giant Cell Tumor: Case Review of a Rare Occurrence | Find, read and cite all the research you need. Giant condyloma acuminatum, originally described by Buschke and Loewenstein in 1925 as a lesion of the penis, is more rarely seen in the anorectum and is characterized by clinical malignancy in the face of histologic benignity; however, malignant transformation to frankly invasive squamous-cell carcinoma has been described. Malignant transformation has been reported in 15 patients with. It is not uncommon for sarcomatous transformation of giant cell tumor (GCT) of bone to occur after radiation, but rarely does malignant transformation occur spontaneously, with less than 15 cases reported up to 1995. Only four of these cases have been documented in detail. We report two additional cases of GCT of bone spontaneously transforming or dedifferentiating into osteosarcoma.
Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against. In giant cell tumor of bone (GCTB), an intermediate malignant bone tumor, approximately 4% of all cases undergo malignant transformation. Accordingly, we analyzed risk factors for malignant transformation of GCTB treated without radiotherapy. We retrospectively reviewed medical records of 530 patients with GCTB [...] Read more
Giant cell tumor of bone (GCTB) is a rare, osteoclasto-genic stromal tumor . GCTB is classified as an inter-mediate, locally aggressive, and rarely metastasizing tumor [2-4], with occasional distant slow-growing me-tastases. Furthermore, GCTB can undergo malignant transformation to high-grade sarcoma, such as osteosar Malignant giant-cell tumors of bone are very rare. These tumors usually present as de novo lesions or, several years after treatment with curettage combined with radiation therapy, as malignant transformation of a benign giant-cell tumor. However, malignant transformation without adjuvant radiation therapy has also been reported1,2,5,8-12,14,16 Giant cell tumors that cannot be excised entirely are often treated with a combination of partial curettage and radiation therapy . The estimated frequency of malignant giant cell tumors or a malignant transformation of benign giant cell tumors is 10% . In most cases, the malignant transformation develops after irradiation Gitelis S, Wang JW, Quast M, Schajowicz F, Templeton A. Recurrence of a giant-cell tumor with malignant transformation to a fibrosarcoma twenty-five years after primary treatment. A case report. J Bone Joint Surg Am. 1989 Jun. 71 (5):757-61. . O'Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ The 2020 World Health Organization classification defined giant cell tumors of bone (GCTBs) as intermediate malignant tumors. Since the mutated H3F3A was found to be a specific marker for GCTB, it has become very useful in diagnosing GCTB. Curettage is the most common treatment for GCTBs. Preoperative administration of denosumab makes curettage difficult and increases the risk of local recurrence
A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases Ira J Miller2, Alan Blank1, Suellen M Yin1, Allison Mcnickle1, Robert Gray1, Steven Gitelis1* Abstract Giant cell tumor (GCT) of bone is a locally destructive tumor that occurs predominantly in long bones of post-pub Giant cell tumors (GCT) are primary bone neoplasms that mainly affect young adults. These tumors are relatively rare and represent about 4.0-9.5% of all bone tumors. 1. While classically, GCTs are benign, they can be locally aggressive and rarely undergo malignant transformation. 2, Secondary malignant giant cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as fever of unknown origin: a case report. Takesako H, Osaka E, Yoshida Y, Sugitani M, Tokuhashi Y. J Med Case Rep, 10:47, 08 Mar 201 There is a probability of the presence of a primary bone sarcoma within prominent areas of giant cell reaction and hemorrhage of a newly discovered GCT that was missed at the initial evaluation instead of a malignant transformation explanation. Malignant transformations result in osteosarcoma, malignant histiocytoma, or fibrosarcoma The term malignant giant cell tumor embraces multiple entities and therefore can be confusing. The goals of the current study were to define the clinicopathologic and histologic features of malignancy in giant cell tumors and to clarify the terminology. 7-28 years) for patients with SMGCT resulting from spontaneous transformation. The.
Malignant giant-cell tumors of bone are very rare. These tumors usually present as de novo lesions or, several years after treatment with curettage combined with radiation therapy, as malignant transformation of a benign giant-cell tumor. However, malignant transformation without adjuvant radiation therapy has also been reported1,2,5,8-12,14,16 Giant cell tumor of bone (GCTB) accounts for approximately 5% to 6% of primary bone tumors. 1,2 It usually occurs in the meta-epiphyseal region of long bones but may also occur in the axial skeleton or small bones of the hands and feet. 3 Giant cell tumor of bone is typically benign but can be locally aggressive; bone disruption can be particularly problematic around joints, compromising joint. closely resembled benign giant cell tumor*31 and giant cell reparative granuloma of bone. '' The giant cells were similar ultrastructurally to normal osteoclasts of bone5* and to those found in giant cell tumor of bone*31 and giant cell FIG. 4. Le/f, Two rnonohistiocytic cells, one of them in mitosis. (X5,OOO.) Rzghf, Typical dark mon
malignant phyllodes tumor is manageable by locally wide excision. Keywords Fibroepithelial lesions, ﬁbroepithelial tumors, giant ﬁbroadenoma, juvenile ﬁbroadenoma, malignant transformation, phyllodes tumor, recurrent tumors. Introduction The transformation of a benign phyllodes tumor into a malignant phyllodes tumor is very uncommon an PRIMARY MALIGNANT GIANT CELL TUMOR OF BONE A Study of Eight Cases and Review of the Literature ANTONIO G. NASCIMENTO, MD, ANDREW G. Huvos, MD, AND RALPH C. MARCOVE, MD Eight cases of primary malignant giant cell tumor of bone were reviewed. There was a wide range in age from 17 to 76 years, with the sixth decade of life being the most common Giant cell tumor, malignant: A type of bone tumor characterized by massive destruction of bone near the end (epiphysis) of a long bone. The site most commonly struck by this tumor is the knee -- the far end of the femur and the near end of the tibia. The tumor is often coated by new bony growth Malignant giant cell tumor of bone (MGCTB) is rare and is currently described as either primary or secondary. Only a few cases have been described in the literature to date. Most published articles on primary malignancy in giant cell tumor of bone (PMGCTB) report a small number of cases. [2-5] PMGCTB is difficult to distinguish from GCTB, and.
Malignant transformation of giant cell tumour of the bone, which could be primary or secondary neoplastic transformation and sarcomatous change, is an extremely rare event.1-3 Receptor activator of nuclear factor kappa B ligand (RANKL) seems to be crucial in the pathogenesis of giant cell tumour, and the RANKL inhibitor denosumab has shown. Borderline ovarian tumor (BOT) refers to a distinct tumor of the ovary of epithelial origin and typically has a favorable prognosis. However, these tumors are not exempt from risks of recurrence and malignant transformation, which can arise from the remaining ovarian tissue, peritoneal implants, or distant localization. Here, we report a case of a mucinous BOT with multiple pulmonary cystic. Background: Although tenosynovial giant cell tumor (TGCT) is classified as a benign tumor, it may undergo malignant transformation and metastasize in extremely rare occasions. High aberrant expression of CSF1 has been implicated in the development of TGCT and recent studies have shown promising activity of several CSF1
Malignant tenosynovial giant cell tumour is defined by the presence of overtly malignant sarcomatous areas. We describe a very unusual case of a 63-year-old man affected by tenosynovial giant cell tumour, diffuse type of the knee that, despite absence of morphologic evidence of sarcomatous transformation, developed inguinal lymph node. The primary bone tumor is usually observed in adolescence age group which has been shown to be part of nearly 20% of the sarcomas known today. Giant cell tumor of bone (GCTB) can be benign as well as malignant tumor which exhibits localized dynamism and is usually associated with the end point of a long bone. Giant cell tumor (GCT) involves mononuclear stromal cells which proliferate at a high.
Giant cell tumor of bone (GCTB) is a biologically benign and locally aggressive tumor that most often affects the epiphyseal and metaphyseal sites of long bones in the young adult population. The aim of the article was to review the clinicopathological characteristics of all the reported cases of malignant sarcomatous transformation of GCTB. Giant cell lesion's of jaw • Malignant neoplasms of constitutes large collection of highly heterogeneous tumors that exhibit a wide spectrum of biologic behaviour, ranging from slow growth & indolence to highly aggressive behaviour & rapid fatality. Neoplastic transformation of the mucus secreting cells C/F:- 1) Appears as. Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor with frequent local recurrence and rare metastasis 1.GCTB typically arises in the metaphysis and epiphysis of long bones and. Giant-cell tumor of the bone ( GCTOB ), is a relatively uncommon tumor of the bone. It is characterized by the presence of multinucleated giant cells ( osteoclast -like cells). Malignancy in giant-cell tumor is uncommon and occurs in about 2% of all cases. However, if malignant degeneration does occur, it is likely to metastasize to the lungs Sacrococcygeal teratomas are tumors originating from pluripotent embryonic germ cell layers located in the fetal coccyx. These tumors are highly vascular if they undergo malignant transformation. Typically, they are found in infants and children and occasionally can be diagnosed prenatally. Adult cases are very rare, and represent tumors present since birth with delayed detection
Giant cell tumor of bone It may be both benign andmalignant. The most common benign tumor variant. 10% of bone giant cell tumors occur malignant, resulting in metastasis to other parts of the body, as well as part of local recurrence after surgical removal. Usually they occur on the upper and lower limbs in young adults and middle-aged people This overexpression results in the transformation of monocytic pre-osteoclast cells to osteoclast cells. These osteoclasts start absorbing the bone resulting in osteolysis seen with these tumors. Histopathology. A giant cell tumor of bone is composed of elongated, oval, or polygonal mononuclear cells with a typical uniform distribution Malignant tenosynovial giant cell tumour is defined by the presence of overtly malignant sarcomatous areas. We describe a very unusual case of a exceed 5% of neoplastic cells. No areas of malignant transformation were identified in the specimen. Four months later a CT scan of the pelvis giant cell tumor of the bone and chondroblastoma.